Product References
A tetracationic porphyrin with dual anti-prion activity.
iScience
Masone A,Zucchelli C,Caruso E,Lavigna G,Eraña H,Giachin G,Tapella L,Comerio L,Restelli E,Raimondi I,Elezgarai SR,De Leo F,Quilici G,Taiarol L,Oldrati M,Lorenzo NL,García-Martínez S,Cagnotto A,Lucchetti J,Gobbi M,Vanni I,Nonno R,Di Bari MA,Tully MD,Cecatiello V,Ciossani G,Pasqualato S,Van Anken E,Salmona M,Castilla J,Requena JR,Banfi S,Musco G,Chiesa R
Published figure using alpha Synuclein monoclonal antibody (Product # 35-8300) in Western Blot
Fri Sep 15 00:00:00 EDT 2023
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Autophagy
Prieto Huarcaya S,Drobny A,Marques ARA,Di Spiezio A,Dobert JP,Balta D,Werner C,Rizo T,Gallwitz L,Bub S,Stojkovska I,Belur NR,Fogh J,Mazzulli JR,Xiang W,Fulzele A,Dejung M,Sauer M,Winner B,Rose-John S,Arnold P,Saftig P,Zunke F
35-8300 was used in Western Blot to indicate that cathepsin D is critical for SNCA clearance and function.
Sun May 01 00:00:00 EDT 2022
Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model While Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels.
Antioxidants (Basel, Switzerland)
Reynolds WF,Malle E,Maki RA
35-8300 was used in Immunohistochemistry-immunofluorescence to suggest that MPO may significantly promote the impairment of the glymphatic waste removal system thus contributing to neurodegeneration in PD and that the inhibition of MPO chlorination/oxidation by SCN- may provide a potential therapeutic approach to this disease.
Sat Nov 26 00:00:00 EST 2022
Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Free radical biology & medicine
Maki RA,Holzer M,Motamedchaboki K,Malle E,Masliah E,Marsche G,Reynolds WF
35-8300 was used in Immunohistochemistry to examine the impact of myeloperoxidase in Parkinson''s disease through analysis of postmortem Parkinson''s disease brain and in a novel animal model in which we crossed a transgenic mouse expressing the human myeloperoxidase gene to a mouse expressing human α-Synuclein-A53T mutant.
Sun Sep 01 00:00:00 EDT 2019
Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Free radical biology & medicine
Maki RA,Holzer M,Motamedchaboki K,Malle E,Masliah E,Marsche G,Reynolds WF
35-8300 was used in Immunohistochemistry to examine the impact of myeloperoxidase in Parkinson''s disease through analysis of postmortem Parkinson''s disease brain and in a novel animal model in which we crossed a transgenic mouse expressing the human myeloperoxidase gene to a mouse expressing human α-Synuclein-A53T mutant.
Sun Sep 01 00:00:00 EDT 2019
Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
Experimental neurology
Wu Q,Yang X,Zhang Y,Zhang L,Feng L
358300 was used in immunohistochemistry to test if chronic stress enhances the progression of Parkinson's disease
Tue Nov 01 00:00:00 EDT 2016
Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate.
Scientific reports
Canron MH,Perret M,Vital A,Bézard E,Dehay B
35-8300 was used in immunohistochemistry to assess Microcebusmurinus as a model of age-related synucleinopathy
Mon May 06 00:00:00 EDT 2013
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.
Annals of neurology
Duda JE,Giasson BI,Mabon ME,Lee VM,Trojanowski JQ
Thu Aug 01 00:00:00 EDT 2002
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.
Annals of neurology
Duda JE,Giasson BI,Mabon ME,Lee VM,Trojanowski JQ
Thu Aug 01 00:00:00 EDT 2002